Tarsus Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tarsus Pharmaceuticals Inc.
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.
BMS, which acquired MyoKardia in 2020 months after LianBio acquired rights in certain Asia-Pacific territories, said the deal would help expand its footprint in China.
Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.
- Topical Delivery
- Drug Delivery
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.